Eversept Partners »

Lipocine shares owned by Eversept Partners

Quarter-by-quarter ownership of Lipocine (LPCN) shares owned by Eversept Partners from 13F filings

Historical chart of Eversept Partners investment in Lipocine

Tip: Access up to 7 years of quarterly data

All positions including Lipocine held by Eversept Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lipocine by Eversept Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.4M 295k 7.99

More positions owned by Eversept Partners

United Therapeutics Corporation (UTHR)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Abivax Sa Sponsored Ads (ABVX)
GSK Sponsored Adr (GSK)
Vera Therapeutics Cl A (VERA)
Natera (NTRA)
State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY)
Syndax Pharmaceuticals (SNDX)
Celldex Therapeutics Com New (CLDX)
Vaxcyte (PCVX)
Brookdale Senior Living (BKD)
Ionis Pharmaceuticals (IONS)
Qiagen Nv Ord Shares (QGEN)
Vertex Pharmaceuticals Incorporated Call Option (VRTX)
Hca Holdings (HCA)

View all positions for Eversept Partners

Top funds holding Lipocine

Ikarian Capital
Squadron Capital Management
Eversept Partners
Vanguard Group
Rosalind Advisors
Vanguard Capital Management
AIGH Capital Management
Stempoint Capital
Boothbay Fund Management
Seven Fleet Capital Management
Birchview Capital
BlackRock
Mink Brook Asset Management
Geode Capital Management
Exome Asset Management

View all funds holding Lipocine